Back to top
more

Merck & Co. (MRK)

(Delayed Data from NYSE)

$113.69 USD

113.69
11,809,273

+0.60 (0.53%)

Updated Sep 27, 2024 04:00 PM ET

After-Market: $113.68 -0.01 (-0.01%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 24% (60 out of 251)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

Merck Buys Rights to Co-Develop Seattle Genetics ADC Drug

Merck (MRK) buys rights to co-develop/co-commercialize Seattle Genetics' ladiratuzumab vedotin. It acquires exclusive license to commercialize Tukysa for HER2-positive cancers in Asia, the Middle East and Latin America

Stock Market News for Sep 15, 2020

U.S. stock markets closed higher on Monday reversing some of the losses of the last week.

M&A Activities Intensify in Pharma Industry

M&A Activities Intensify in Pharma Industry.

Mark Vickery headshot

No Econ Data, but Big Biopharma News

Merck, Gilead and Lilly make progress on an otherwise slow news day.

Kinjel Shah headshot

Pharma Stock Roundup: AZN & PFE's Coronavirus Vaccine Updates & FDA Approvals

AstraZeneca (AZN) halts coronavirus vaccine study. FDA approves Roche (RHHBY) and Glaxo's (GSK) medicines.

Zacks Market Edge Highlights: MRK, ABBV, PXD, VBR and VIOO

Zacks Market Edge Highlights: MRK, ABBV, PXD, VBR and VIOO

Merck's Pneumococcal Vaccine Meets Goals in Late-Stage Studies

Merck's (MRK) investigational 15-valent pneumococcal conjugate vaccine meets primary immunogenicity objectives in two late-stage studies in adults.

Merck (MRK) Gains But Lags Market: What You Should Know

Merck (MRK) closed at $84.88 in the latest trading session, marking a +1.86% move from the prior day.

Tracey Ryniec headshot

Generation X Investors: Deja Vu?

Generation X investors came of age in the dot-com boom when Microsoft and other tech titans hit new highs. Now, in 2020, it's happening again.

Merck Announces Detailed Data on Late-Stage Cough Candidate

Merck (MRK) announced detailed data from two pivotal studies evaluating gefapixant in patients with refractory or unexplained chronic cough.

Kinjel Shah headshot

CEOs of Nine Coronavirus Vaccine Makers Sign Safety Pledge

The COVID-19 vaccine developers pledge to observe high ethical standards and sound scientific principles in conducting clinical studies and manufacturing of vaccines.

Kinjel Shah headshot

Coronavirus Vaccine Efforts Hit as AstraZeneca Halts Study

Amid rising optimism on timely approval of a safe vaccine, the vaccine development efforts of AstraZeneca (AZN) have hit a roadblock.

Here's Why AstraZeneca (AZN) Stock is Up This Year So Far

AstraZeneca's (AZN) shares are up this year mainly due to rapid progress in its efforts to make a vaccine to treat COVID-19 as well as other positive pipeline and regulatory updates.

Lilly (LLY) Gets FDA Approval for Higher Doses of Trulicity

Lilly's (LLY) higher doses of Trulicity led to superior reductions in blood glucose level and weight in type II diabetes patients compared to the currently available dose.

J&J to Stop Development of Influenza Candidate Pimodivir

Johnson & Johnson (JNJ) to halt the development of pimodivir, an investigational antiviral treatment of influenza A infection.

Innoviva (INVA) in Focus: Stock Moves 7% Higher

Innoviva (INVA) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.

Sanghamitra Saha headshot

Dow Jones Tops 29,000: Will ETFs & Stocks Rally in September?

The Dow jumped above 29,000 for the first time since February on Sep 2 on low rates and vaccine hopes.

Bristol Myers Gets FDA Approval for Oral AML Therapy Onureg

Bristol Myers' (BMY) Onureg becomes the first and only FDA-approved continued AML therapy for patients in remission.

AstraZeneca's Imfinzi Gets EU Approval for First-Line SCLC

AstraZeneca's (AZN) Imfinzi gets approval in Europe to treat extensive-stage small cell lung cancer.

The Zacks Analyst Blog Highlights: CRM, MRK, T, NKE and GSK

The Zacks Analyst Blog Highlights: CRM, MRK, T, NKE and GSK

Are You Looking for a High-Growth Dividend Stock? Merck (MRK) Could Be a Great Choice

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Merck (MRK) have what it takes? Let's find out.

Bayer Submits Application for Heart Failure Drug in China

Bayer (BAYRY) submits a regulatory application seeking approval for vericiguat to treat patients with symptomatic chronic heart failure in China.

Kinjel Shah headshot

Pharma Stock Roundup: AZN's Coronavirus Antibody Combo Study, & Other Updates

AstraZeneca (AZN) begins dosing in phase I study on antibody cocktail therapy to treat COVID-19. Glaxo's (GSK) Blenrep gets approval in Europe.

Sheraz Mian headshot

Top Analyst Reports for Salesforce, Merck & AT&T

Today's Research Daily features new research reports on 16 major stocks, including salesforce.com (CRM), Merck Co. (MRK) and AT&T (T).

Why Is Merck (MRK) Up 8.4% Since Last Earnings Report?

Merck (MRK) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.